Drug Profile
Research programme: therapeutic antibodies - Adimab/Innovent Biologics
Latest Information Update: 28 Jul 2018
Price :
$50
*
At a glance
- Originator Adimab; Innovent Biologics
- Class Antibodies
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Unspecified
Most Recent Events
- 28 Jul 2018 No recent reports of development identified for research development in Undefined in USA (Parenteral)
- 21 Aug 2013 Early research in Undefined indication in USA (Parenteral)